Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585312 · ClinicalTrials.gov registry record · Phase 3
Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Terminated
- Registry status
- Phase 3
- Development phase
- 106
- Enrollment target
NCT00585312 is a Phase 3 study that was terminated before completion, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 106 participants.
The verdict
NCT00585312, a Phase 3 study, was terminated before completion, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 106 participants
- Enrollment target
Study Summary
To test whether celecoxib can be used to prevent colon polyp formation in children with familial adenomatous polyposis (FAP).
Interventions
- DRUG Placebo
- DRUG Celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2006-09 |
| Est. Completion | 2013-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00585312
The ClinicalTrials.gov registry entry for NCT00585312 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00585312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00585312 about?
NCT00585312 is a clinical study titled "Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)". To test whether celecoxib can be used to prevent colon polyp formation in children with familial adenomatous polyposis (FAP).
What is the current status of trial NCT00585312?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 106 participants. The study started on 2006-09. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00585312?
The interventions under investigation include: Placebo (DRUG), Celecoxib (DRUG).
Who is sponsoring clinical trial NCT00585312?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.